These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 21355079)

  • 1. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
    Roccaro AM; Sacco A; Aujay M; Ngo HT; Azab AK; Azab F; Quang P; Maiso P; Runnels J; Anderson KC; Demo S; Ghobrial IM
    Blood; 2010 May; 115(20):4051-60. PubMed ID: 20110419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
    Roccaro AM; Leleu X; Sacco A; Jia X; Melhem M; Moreau AS; Ngo HT; Runnels J; Azab A; Azab F; Burwick N; Farag M; Treon SP; Palladino MA; Hideshima T; Chauhan D; Anderson KC; Ghobrial IM
    Blood; 2008 May; 111(9):4752-63. PubMed ID: 18316628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
    Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
    Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
    Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
    Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
    Parlati F; Lee SJ; Aujay M; Suzuki E; Levitsky K; Lorens JB; Micklem DR; Ruurs P; Sylvain C; Lu Y; Shenk KD; Bennett MK
    Blood; 2009 Oct; 114(16):3439-47. PubMed ID: 19671918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
    Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
    Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
    PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of proteasome inhibition in Waldenström's macroglobulinemia.
    Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
    Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
    Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
    Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
    Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.